Treatment Advances

July 16, 2025

Learn how the mosunetuzumab and polatuzumab vedotin combination triples remission time in relapsed large B-cell lymphoma.

July 02, 2025

Learn how the FDA’s decision to remove safety restrictions for CAR T-cell therapy could improve access for people with blood cancer.

July 01, 2025

In vivo CAR T-cell therapy may make blood cancer treatment safer, faster, and more accessible.

June 16, 2025

Pola-R-GemOx improves survival in relapsed/refractory DLBCL compared to R-GemOx alone, per results from the POLARGO Phase III trial.

June 03, 2025

Pemivibart has been added to oncology guidelines as a COVID-19 prevention option for people with B-cell lymphoma.

May 23, 2025

The glofitamab with GemOx study shows 40% survival benefit in relapsed/refractory DLBCL.

April 25, 2025

Discover how glofitamab is transforming DLBCL treatment with durable responses, new combinations, and promising clinical trial results.

April 18, 2025

Learn more about updates of golcadomide in combination with other treatments for high-risk aggressive lymphoma.

March 28, 2025

New studies explore chemo-free treatments for relapsed non-Hodgkin lymphoma, including bispecific antibodies and all-oral options.

March 06, 2025

Explore recent trial results on mosunetuzumab + polatuzumab for R/R LBCL, showing higher response rates & longer remission vs. standard care.